Body cell therapy for hepatitis B. The therapy simply means using your own cells to treat your own disease. This technique does not use drugs and does not require surgery. It involves extracting 50 ml of immune cells from the patient’s blood through cell harvesting equipment, then inducing and culturing these cells in a cell chamber so that they develop into healthy, mature cells with appropriate immune functions, restoring their ability to kill the hepatitis B virus, then causing the cells to multiply hundreds of times, and finally infusing these cells back into the patient’s body to kill the virus in the blood and The cells are then transfused back into the patient to kill the virus in the blood and in the liver cells. The process of cellular therapy for hepatitis B begins with the collection and isolation of immune cells from the blood of the patient with hepatitis B. The cells are trained and cultured in vitro using the patient’s own cells and then cultured to have the ability to attack the hepatitis B virus. -The cells are then returned to the hepatitis B patient – and the cells returned to the body are used to destroy the hepatitis B virus in the blood and liver. Features of somatic cell therapy for hepatitis B Targeted: specifically attacks the hepatitis B virus without any effect on normal liver cells and other body tissues. Targeted CIK technology for chronic hepatitis B treatment involves in vitro induction and expansion of monocytes into CIK cells with a variety of cytokines, followed by the addition of hepatitis B virus-specific antigens to cause these killer cells to proliferate and recognize information about the hepatitis B virus, and then return them to the body to achieve the effect of specifically killing the hepatitis B virus. The use of in vitro cultured targeted CIK cells can effectively compensate for the shortage of specific killer cells in chronic hepatitis B patients due to immune tolerance, thus achieving the goal of hepatitis B treatment. Longevity: The cultured mature cells can survive for years to decades after transfusion back into the body, providing long-term protection against relapse or reinfection and stopping the process of liver fibrosis and early cirrhosis. Safety: Since the treatment process is based on the application of automatic blood cell separator and disposable consumables to collect single nucleated cells from the patient’s peripheral blood, then under sterile conditions (class 1000 clean laminar flow laboratory, class 100 biosafety cabinet), the collected single nucleated cells are cultured with a variety of cytokines to make the patient’s immune cells expand in large numbers and increase in activity, inducing them to become powerful virus-killing The cells are then infused back into the patient’s body intravenously to specifically kill the virus and enhance the patient’s overall immune function. This therapy is an auto-immune cell transfusion treatment, which does not produce rejection, has no side effects and has good safety. According to Health News, “the rate of HBeAg conversion for hepatitis B can reach 90%”. Due to the complexity of the operation, general hospitals can not carry out; expensive, it is difficult for general patients to survive.